Dupilumab for severe eczema with limited skin rash
Treatments studied
Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.
This study looks at how well dupilumab works for children and teens with severe eczema (atopic dermatitis) even when the rash is not widespread. It aims to see if the treatment helps with itching, quality of life, and rashes in visible or sensitive areas.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 6 months and 17 years old.
- You must have been prescribed dupilumab by your doctor as part of your regular care.
- Your eczema severity score (EASI) must be below a certain level: less than 16 for teens (12-17) and less than 21 for children (6 months to 11 years).
- You must have at least one of the following: a Children's Dermatology Life Quality Index (cDLQI) score of 10 or more, an itch score (NRS) of 7 or more, or eczema in visible or sensitive areas like the head, neck, hands, or genitals.
- You or your caregiver must be able to understand and fill out study questionnaires.
- You must not have used dupilumab in the last 6 months, and you cannot be in another clinical trial that changes your care.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well Dupilumab works over time for people with atopic dermatitis (eczema). It includes adults, teens, and children ages 6 and up.
This study tests whether an oral medicine (upadacitinib) works as well as a shot (dupilumab) for children aged 2 to 12 with moderate to severe eczema. It aims to see which treatment better controls symptoms like itching and skin rashes.
This trial studies whether dupilumab can improve daily body clock (circadian function), sleep, and itching in children with moderate-to-severe eczema that isn’t well controlled by creams. It may help kids who are having significant sleep trouble and ongoing itch.
This trial studies how the body’s “molecular signals” change in the skin after using dupilumab for eczema. It may help researchers understand who benefits most from treatment.
This Phase 4 study looks at how dupilumab works in people with moderate-to-severe atopic dermatitis (eczema), and whether the mechanism differs across ethnic backgrounds. If you’re eligible, it may help doctors understand who benefits most from dupilumab.
This trial studies why eczema (“atopic dermatitis”) varies in severity even when people receive the medicine dupilumab. It may help doctors better predict who responds well and how to monitor treatment.
Hear when a new Atopic Dermatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.